The massive dilutive offering will likely pressure QTTB shares near term. Watch for any positive pipeline updates or insider buying to gauge sentiment. The rapid execution under a recently declared effective shelf suggests urgency in capital needs.
Price Chart
Executive Summary
Q32 Bio priced a $200 million underwritten public offering of common stock and pre-funded warrants, representing massive dilution of approximately 55% relative to its $363M market cap. The proceeds will fund working capital and clinical development of bempikibart for alopecia areata. The offering is expected to close July 16, 2026.
Key Financial Metrics
Key Facts
- $200 million gross proceeds from public offering of 6,027,399 shares at $18.25 and 4,931,506 pre-funded warrants at $18.2499
- Underwriters have a 30-day option to purchase up to an additional 1,643,835 shares at the offering price
- Proceeds to be used for working capital, including clinical development and commercialization of bempikibart
- Offering expected to close on or about July 16, 2026
- Offering represents approximately 55% dilution relative to current market cap of $363M
Financial Impact
Approximately $200 million gross proceeds, with dilution of over 50% of current shares outstanding
Risk Factors
- Significant shareholder dilution from the offering
- Potential for further offerings if cash runway is insufficient
- Clinical trial risk for bempikibart in alopecia areata
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302825849 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.23 (−24.56%) |
Aug 27, 2026 5w ago | Insider Cluster | $16.15 $12.80 | ▼ −20.74% | ▼ −21.01% | $8.23 (−49.04%) |
Aug 5, 2026 8w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.23 (−50.09%) |
Jul 15, 2026 11w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.23 (+47.58%) |
Jul 14, 2026 11w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.23 (−55.42%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.23 (−61.51%) |
Jun 25, 2026 14w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.23 (−37.51%) |
Jun 2, 2026 17w ago | Insider Cluster | $12.64 $11.89 | ▼ −5.93% | ▼ −2.97% | $8.23 (−34.89%) |
May 5, 2026 21w ago | 8-K | $5.14 $5.81 | ▲ +13.04% | ▲ +11.05% | $8.23 (+60.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access